Guizhou Xinbang Pharmaceutical Co Ltd (002390) — Working Capital to Net Assets Ratio
Guizhou Xinbang Pharmaceutical Co Ltd (002390) has a Working Capital to Net Assets ratio of 50.9% as of September 2025. Working capital of CN¥3.55 Billion (current assets of CN¥4.93 Billion minus current liabilities of CN¥1.38 Billion) is measured against net assets of CN¥6.97 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Guizhou Xinbang Pharmaceutical Co Ltd Working Capital to Net Assets (2006–2024)
This chart shows how Guizhou Xinbang Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2006 to 2024. As of September 2025, the ratio stands at 50.9%, reflecting working capital of CN¥3.55 Billion against net assets of CN¥6.97 Billion CNY. Explore how much of Guizhou Xinbang Pharmaceutical Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Annual Working Capital to Net Assets for Guizhou Xinbang Pharmaceutical Co Ltd (2006–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Guizhou Xinbang Pharmaceutical Co Ltd from 2006 to 2024, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 002390 total asset value.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 49.1% | CN¥3.45 Billion | CN¥7.02 Billion | CN¥5.25 Billion | CN¥1.81 Billion | ▲ +2.1 pp |
| 2023 | 46.9% | CN¥3.35 Billion | CN¥7.14 Billion | CN¥5.41 Billion | CN¥2.06 Billion | ▲ +2.8 pp |
| 2022 | 44.2% | CN¥3.12 Billion | CN¥7.07 Billion | CN¥5.81 Billion | CN¥2.69 Billion | ▲ +2.8 pp |
| 2021 | 41.3% | CN¥2.82 Billion | CN¥6.83 Billion | CN¥5.58 Billion | CN¥2.75 Billion | ▲ +10.0 pp |
| 2020 | 31.4% | CN¥1.62 Billion | CN¥5.17 Billion | CN¥6.09 Billion | CN¥4.47 Billion | ▲ +8.3 pp |
| 2019 | 23.1% | CN¥1.17 Billion | CN¥5.05 Billion | CN¥6.18 Billion | CN¥5.01 Billion | ▼ -2.8 pp |
| 2018 | 25.9% | CN¥1.34 Billion | CN¥5.17 Billion | CN¥6.67 Billion | CN¥5.34 Billion | ▲ +4.2 pp |
| 2017 | 21.7% | CN¥1.46 Billion | CN¥6.76 Billion | CN¥6.34 Billion | CN¥4.87 Billion | ▲ +0.7 pp |
| 2016 | 20.9% | CN¥1.36 Billion | CN¥6.49 Billion | CN¥5.64 Billion | CN¥4.28 Billion | ▲ +18.9 pp |
| 2015 | 2.1% | CN¥55.48 Million | CN¥2.67 Billion | CN¥3.83 Billion | CN¥3.77 Billion | ▼ -23.0 pp |
| 2014 | 25.1% | CN¥615.83 Million | CN¥2.46 Billion | CN¥3.32 Billion | CN¥2.71 Billion | ▼ -35.5 pp |
| 2013 | 60.6% | CN¥627.37 Million | CN¥1.04 Billion | CN¥1.05 Billion | CN¥426.93 Million | ▼ -3.5 pp |
| 2012 | 64.0% | CN¥654.85 Million | CN¥1.02 Billion | CN¥946.10 Million | CN¥291.25 Million | ▼ -6.6 pp |
| 2011 | 70.7% | CN¥692.36 Million | CN¥979.53 Million | CN¥945.47 Million | CN¥253.12 Million | ▼ -7.6 pp |
| 2010 | 78.3% | CN¥751.07 Million | CN¥959.70 Million | CN¥916.86 Million | CN¥165.79 Million | ▲ +34.7 pp |
| 2009 | 43.6% | CN¥110.15 Million | CN¥252.83 Million | CN¥324.15 Million | CN¥214.00 Million | ▲ +13.5 pp |
| 2008 | 30.0% | CN¥62.41 Million | CN¥207.69 Million | CN¥291.47 Million | CN¥229.07 Million | ▼ -0.1 pp |
| 2007 | 30.2% | CN¥52.52 Million | CN¥174.08 Million | CN¥240.43 Million | CN¥187.90 Million | ▲ +12.6 pp |
| 2006 | 17.6% | CN¥25.33 Million | CN¥144.17 Million | CN¥231.21 Million | CN¥205.88 Million | — |